Why ovarian risk is addressed early
For people with harmful BRCA1 or BRCA2 variants, risk-reducing salpingo-oophorectomy—removal of both fallopian tubes and ovaries—is the established surgical strategy for substantially reducing ovarian, fallopian-tube, and primary peritoneal cancer risk. It does not reduce risk to zero, and timing is gene- and person-specific.
Transvaginal ultrasound and CA-125 may be discussed in selected circumstances, but they have not been shown to be an effective substitute for risk-reducing surgery. The decision should involve a gynecologic oncologist, not a screening slogan.
What “ovary sparing” actually means
The studied strategy is generally risk-reducing salpingectomy with delayed oophorectomy: tubes are removed first and ovaries are removed later. It aims to delay surgical menopause, but the key unanswered question is whether it prevents cancer as effectively as removing tubes and ovaries together.
Ask whether a clinical trial is available, what surveillance is used during the delay, the planned age for oophorectomy, and what would trigger a change in timing. A staged approach still requires a second operation and does not eliminate the need for later ovarian removal.
The operation is also a pathology event
The surgical plan should identify who performs the procedure, how the tubes and ovaries will be processed by pathology, what happens if an occult lesion is found, and whether pelvic washings or additional procedures are expected. Patients should request the operative report and final pathology report for their permanent file.
- Settle fertility and family-building questions before an irreversible procedure.
- Prepare the menopause treatment plan before surgery, not at the first severe symptom.
- Document residual primary peritoneal risk and the symptoms that warrant evaluation afterward.